What the FDA labels say about taking them together
Glucagon and octreotide
Octreotide's FDA label of July 22, 2026 names glucagon in its drug interactions section; the glucagon labels PlainMeds reads (4) do not name octreotide. The octreotide label: “Injection alters the balance between the counter-regulatory hormones, insulin, glucagon and GH, which may result in hypoglycemia or hyperglycemia.”
Check it at the source: the glucagon FDA label on DailyMed (effective August 11, 2026, Amphastar Pharmaceuticals, Inc.); the octreotide FDA label on DailyMed (effective July 22, 2026, Novartis Pharmaceuticals Corporation).
What does the glucagon label say about octreotide?
Glucagon's label (effective August 11, 2026) and its 3 other brand-application labels do not name octreotide in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Glucagon), Amphastar Pharmaceuticals, Inc., effective August 11, 2026 (SPL set 8cc40354-b5ac-45b6-a211-93b44444f2a3), via openFDA; the full label on DailyMed
What does the octreotide label say about glucagon?
Octreotide label, drug interactionsOctreotide inhibits the secretion of insulin and glucagon.
Octreotide label, warnings and precautionsInjection alters the balance between the counter-regulatory hormones, insulin, glucagon and GH, which may result in hypoglycemia or hyperglycemia.
Mycapssa label (Chiesi USA, Inc., July 24, 2025), drug interactionsClinical Impact: MYCAPSSA inhibits the secretion of insulin and glucagon. Intervention: Monitor blood glucose levels in diabetic patients upon MYCAPSSA initiation and subsequent dose adjustment. Patients receiving insulin or antidiabetic drugs agents may require dose adjustment of these therapeutic agents.
Source: FDA drug label (Sandostatin Lar Depot, NDA021008), Novartis Pharmaceuticals Corporation, effective December 22, 2025 (SPL set d0b7fe9e-7000-4b79-ba3b-291ce92c14f9), via openFDA
Source: FDA drug label (Mycapssa, NDA208232), Chiesi USA, Inc., effective July 24, 2025 (SPL set 58d80bc6-bdfb-4908-93e7-aace447c8d1a), via openFDA
Source: FDA drug label (Sandostatin), Novartis Pharmaceuticals Corporation, effective July 22, 2026 (SPL set 4e2c9856-1836-49f0-9472-4dbeeb408f39), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Glucagon | Octreotide | |
|---|---|---|
| Labeled for | n/a | Diarrhea |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $154.20 per kit 1 mg emergency kit | $2.53 per mL 100 mcg/mL vial |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once